Aim 100: 100-91

Aim 100: 100-91

100. Vernalis

A tough year for Vernalis (VER) has seen it only just cling on to its place in the Aim 100. The share price of the cough and cold drugs specialist has been battered after sales of its first ‘home grown’ drug, Tuzistra, failed to take off as expected in the US. Chief executive Ian Garland admitted that the group hadn’t managed to get its commercial operations off the ground as quickly as hoped.

But more recent signs are encouraging. In early March, even as the wider cough and cold season was slowing, Tuzistra enjoyed a 4 per cent rise in weekly prescriptions, meaning the group looks on track to reach broker Panmure Gordon’s full-year sales forecast of £15.8m. More encouraging still is the progress of the new drugs pipeline. Vernalis has two more cough and cold remedies in the late stage of clinical trials, due to announce results this year. Buy. MB

To continue reading, subscribe today

and enjoy unlimited access to the following:

  • Tips of the Week
  • Funds coverage
  • Weekly features on big investment themes
  • Trading ideas
  • Comprehensive companies coverage
  • Economic analysis
Subscribe to Investors Chronicle

Related topics

Subscribe today

Full access for just £3.37 a week:

• Tips and recommendations - to beat the market 
• Portfolio clinic & Mr Bearbull - build a well-planned portfolio 
• Expert tools - track and manage investments effortlessly
• Plus free delivery to your home or office

Subscribe Now